Stockreport

Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update

Cardiff Oncology, Inc.  (CRDF) 
PDF – Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colore [Read more]